170 related articles for article (PubMed ID: 36151568)
1. Association of Alzheimer's disease polygenic risk scores with amyloid accumulation in cognitively intact older adults.
Luckett ES; Abakkouy Y; Reinartz M; Adamczuk K; Schaeverbeke J; Verstockt S; De Meyer S; Van Laere K; Dupont P; Cleynen I; Vandenberghe R
Alzheimers Res Ther; 2022 Sep; 14(1):138. PubMed ID: 36151568
[TBL] [Abstract][Full Text] [Related]
2. Amyloid-β and APOE genotype predict memory decline in cognitively unimpaired older individuals independently of Alzheimer's disease polygenic risk score.
Tomassen J; den Braber A; van der Lee SJ; Reus LM; Konijnenberg E; Carter SF; Yaqub M; van Berckel BNM; Collij LE; Boomsma DI; de Geus EJC; Scheltens P; Herholz K; Tijms BM; Visser PJ
BMC Neurol; 2022 Dec; 22(1):484. PubMed ID: 36522743
[TBL] [Abstract][Full Text] [Related]
3. Association of
Xicota L; Gyorgy B; Grenier-Boley B; Lecoeur A; Fontaine G; Danjou F; Gonzalez JS; Colliot O; Amouyel P; Martin G; Levy M; Villain N; Habert MO; Dubois B; Lambert JC; Potier MC;
Neurology; 2022 Aug; 99(5):e462-e475. PubMed ID: 35606148
[TBL] [Abstract][Full Text] [Related]
4. Longitudinal changes in
Luckett ES; Schaeverbeke J; De Meyer S; Adamczuk K; Van Laere K; Dupont P; Vandenberghe R
Neuroimage Clin; 2023; 37():103321. PubMed ID: 36621019
[TBL] [Abstract][Full Text] [Related]
5. Tau polygenic risk scoring: a cost-effective aid for prognostic counseling in Alzheimer's disease.
Ramanan VK; Heckman MG; Lesnick TG; Przybelski SA; Cahn EJ; Kosel ML; Murray ME; Mielke MM; Botha H; Graff-Radford J; Jones DT; Lowe VJ; Machulda MM; Jack CR; Knopman DS; Petersen RC; Ross OA; Vemuri P
Acta Neuropathol; 2022 May; 143(5):571-583. PubMed ID: 35412102
[TBL] [Abstract][Full Text] [Related]
6. Longitudinal APOE4- and amyloid-dependent changes in the blood transcriptome in cognitively intact older adults.
Luckett ES; Zielonka M; Kordjani A; Schaeverbeke J; Adamczuk K; De Meyer S; Van Laere K; Dupont P; Cleynen I; Vandenberghe R
Alzheimers Res Ther; 2023 Jul; 15(1):121. PubMed ID: 37438770
[TBL] [Abstract][Full Text] [Related]
7. Utility of an Alzheimer's Disease Risk-Weighted Polygenic Risk Score for Predicting Rates of Cognitive Decline in Preclinical Alzheimer's Disease: A Prospective Longitudinal Study.
Porter T; Burnham SC; Milicic L; Savage G; Maruff P; Lim YY; Li QX; Ames D; Masters CL; Rainey-Smith S; Rowe CC; Salvado O; Groth D; Verdile G; Villemagne VL; Laws SM;
J Alzheimers Dis; 2018; 66(3):1193-1211. PubMed ID: 30412495
[TBL] [Abstract][Full Text] [Related]
8. Polygenic Scores of Alzheimer's Disease Risk Genes Add Only Modestly to APOE in Explaining Variation in Amyloid PET Burden.
Ramanan VK; Heckman MG; Przybelski SA; Lesnick TG; Lowe VJ; Graff-Radford J; Mielke M; Jack CR; Knopman DS; Petersen RC; Ross OA; Vemuri P;
J Alzheimers Dis; 2022; 88(4):1615-1625. PubMed ID: 35811524
[TBL] [Abstract][Full Text] [Related]
9. The accumulation rate of tau aggregates is higher in females and younger amyloid-positive subjects.
Smith R; Strandberg O; Mattsson-Carlgren N; Leuzy A; Palmqvist S; Pontecorvo MJ; Devous MD; Ossenkoppele R; Hansson O
Brain; 2020 Dec; 143(12):3805-3815. PubMed ID: 33439987
[TBL] [Abstract][Full Text] [Related]
10. Prediction of clinical diagnosis of Alzheimer's disease, vascular, mixed, and all-cause dementia by a polygenic risk score and APOE status in a community-based cohort prospectively followed over 17 years.
Stocker H; Perna L; Weigl K; Möllers T; Schöttker B; Thomsen H; Holleczek B; Rujescu D; Brenner H
Mol Psychiatry; 2021 Oct; 26(10):5812-5822. PubMed ID: 32404947
[TBL] [Abstract][Full Text] [Related]
11. Alzheimer's polygenic risk scores, APOE, Alzheimer's disease risk, and dementia-related blood biomarker levels in a population-based cohort study followed over 17 years.
Stocker H; Trares K; Beyer L; Perna L; Rujescu D; Holleczek B; Beyreuther K; Gerwert K; Schöttker B; Brenner H
Alzheimers Res Ther; 2023 Jul; 15(1):129. PubMed ID: 37516890
[TBL] [Abstract][Full Text] [Related]
12. Synergistic interaction between APOE and family history of Alzheimer's disease on cerebral amyloid deposition and glucose metabolism.
Yi D; Lee Y; Byun MS; Lee JH; Ko K; Sohn BK; Choe YM; Choi HJ; Baek H; Sohn CH; Kim YK; Lee DY;
Alzheimers Res Ther; 2018 Aug; 10(1):84. PubMed ID: 30134963
[TBL] [Abstract][Full Text] [Related]
13. Genetic risk for alzheimer disease is distinct from genetic risk for amyloid deposition.
Leonenko G; Shoai M; Bellou E; Sims R; Williams J; Hardy J; Escott-Price V;
Ann Neurol; 2019 Sep; 86(3):427-435. PubMed ID: 31199530
[TBL] [Abstract][Full Text] [Related]
14. KL∗VS heterozygosity reduces brain amyloid in asymptomatic at-risk APOE∗4 carriers.
Belloy ME; Eger SJ; Le Guen Y; Napolioni V; Deters KD; Yang HS; Scelsi MA; Porter T; James SN; Wong A; Schott JM; Sperling RA; Laws SM; Mormino EC; He Z; Han SS; Altmann A; Greicius MD; ; ; ;
Neurobiol Aging; 2021 May; 101():123-129. PubMed ID: 33610961
[TBL] [Abstract][Full Text] [Related]
15. Digital Clock Drawing as an Alzheimer's Disease Susceptibility Biomarker: Associations with Genetic Risk Score and APOE in Older Adults.
Thompson LI; Cummings M; Emrani S; Libon DJ; Ang A; Karjadi C; Au R; Liu C
J Prev Alzheimers Dis; 2024; 11(1):79-87. PubMed ID: 38230720
[TBL] [Abstract][Full Text] [Related]
16. Correlations between APOE4 allele and regional amyloid and tau burdens in cognitively normal older individuals.
Hong YJ; Kim CM; Lee JH; Sepulcre J
Sci Rep; 2022 Aug; 12(1):14307. PubMed ID: 35995824
[TBL] [Abstract][Full Text] [Related]
17. Genetically-regulated pathway-polygenic risk score (GRPa-PRS): A risk stratification method to identify genetically regulated pathways in polygenic diseases.
Li X; Fernandes BS; Liu A; Lu Y; Chen J; Zhao Z; Dai Y
medRxiv; 2023 Jun; ():. PubMed ID: 37425929
[TBL] [Abstract][Full Text] [Related]
18. APOE modulates the effect of estrogen therapy on Aβ accumulation EFAD-Tg mice.
Kunzler J; Youmans KL; Yu C; Ladu MJ; Tai LM
Neurosci Lett; 2014 Feb; 560():131-6. PubMed ID: 24368217
[TBL] [Abstract][Full Text] [Related]
19. Cognitive and neuroimaging features and brain β-amyloidosis in individuals at risk of Alzheimer's disease (INSIGHT-preAD): a longitudinal observational study.
Dubois B; Epelbaum S; Nyasse F; Bakardjian H; Gagliardi G; Uspenskaya O; Houot M; Lista S; Cacciamani F; Potier MC; Bertrand A; Lamari F; Benali H; Mangin JF; Colliot O; Genthon R; Habert MO; Hampel H;
Lancet Neurol; 2018 Apr; 17(4):335-346. PubMed ID: 29500152
[TBL] [Abstract][Full Text] [Related]
20. Neuroimaging biomarkers for Alzheimer's disease in asymptomatic APOE4 carriers.
Chételat G; Fouquet M
Rev Neurol (Paris); 2013 Oct; 169(10):729-36. PubMed ID: 24016463
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
